Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Summit Therapeutics ( (SMMT) ) just unveiled an update.
On August 11, 2025, Summit Therapeutics amended its distribution agreement with J.P. Morgan Securities to increase the offering price of its common stock by an additional $360 million. This amendment allows the company to sell shares through the Sales Agent at market prices or negotiated prices, with no obligation to sell, potentially enhancing its financial flexibility and market presence.
The most recent analyst rating on (SMMT) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.
Spark’s Take on SMMT Stock
According to Spark, TipRanks’ AI Analyst, SMMT is a Neutral.
Summit Therapeutics’ stock score reflects significant financial challenges, including lack of revenue and ongoing losses, balanced by a strong equity position. Technical indicators show positive momentum, supporting short-term interest. Valuation remains weak due to negative earnings and no dividend. Positive clinical developments from the earnings call bolster the score, highlighting potential for future growth.
To see Spark’s full report on SMMT stock, click here.
More about Summit Therapeutics
Summit Therapeutics Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for rare diseases and other unmet medical needs.
Average Trading Volume: 3,802,628
Technical Sentiment Signal: Buy
Current Market Cap: $21.28B
See more data about SMMT stock on TipRanks’ Stock Analysis page.